Published in Eur J Heart Fail on March 27, 2010
Transcriptional mechanisms regulating skeletal muscle differentiation, growth and homeostasis. Nat Rev Mol Cell Biol (2011) 2.51
The role of myostatin in muscle wasting: an overview. J Cachexia Sarcopenia Muscle (2011) 1.36
Telethonin deficiency is associated with maladaptation to biomechanical stress in the mammalian heart. Circ Res (2011) 1.07
Myostatin from the heart: local and systemic actions in cardiac failure and muscle wasting. Am J Physiol Heart Circ Physiol (2011) 1.03
Biochemistry and Biology of GDF11 and Myostatin: Similarities, Differences, and Questions for Future Investigation. Circ Res (2016) 0.98
Satellite cells in human skeletal muscle plasticity. Front Physiol (2015) 0.96
Association of handgrip strength with chronic diseases and multimorbidity: a cross-sectional study. Age (Dordr) (2012) 0.96
Targeting the myostatin signaling pathway to treat muscle wasting diseases. Curr Opin Support Palliat Care (2011) 0.96
Treating cancer cachexia to treat cancer. Skelet Muscle (2011) 0.95
New and emerging biomarkers in left ventricular systolic dysfunction--insight into dilated cardiomyopathy. J Cardiovasc Transl Res (2013) 0.87
Myostatin is upregulated following stress in an Erk-dependent manner and negatively regulates cardiomyocyte growth in culture and in a mouse model. PLoS One (2010) 0.87
Cardiac myostatin upregulation occurs immediately after myocardial ischemia and is involved in skeletal muscle activation of atrophy. Biochem Biophys Res Commun (2014) 0.85
Myostatin is elevated in congenital heart disease and after mechanical unloading. PLoS One (2011) 0.85
Metabolic and structural impairment of skeletal muscle in heart failure. Heart Fail Rev (2013) 0.84
Highly specific detection of myostatin prodomain by an immunoradiometric sandwich assay in serum of healthy individuals and patients. PLoS One (2013) 0.82
Skeletal muscle protein metabolism in human heart failure. Curr Opin Clin Nutr Metab Care (2013) 0.81
Myocardial remodeling, an overview. Heart Fail Rev (2011) 0.79
Pitx2c is reactivated in the failing myocardium and stimulates myf5 expression in cultured cardiomyocytes. PLoS One (2014) 0.78
Myostatin regulates tissue potency and cardiac calcium-handling proteins. Endocrinology (2014) 0.78
Myostatin: an overlooked player in heart failure? Eur J Heart Fail (2010) 0.78
Muscle wasting and cachexia in heart failure: mechanisms and therapies. Nat Rev Cardiol (2017) 0.78
Cardiac cachexia: hic et nunc. J Cachexia Sarcopenia Muscle (2016) 0.78
Molecular pathways leading to loss of skeletal muscle mass in cancer cachexia - can findings from animal models be translated to humans? BMC Cancer (2016) 0.77
Myostatin serum levels in heart failure. Eur J Heart Fail (2010) 0.77
Cardiac-Secreted Factors as Peripheral Metabolic Regulators and Potential Disease Biomarkers. J Am Heart Assoc (2016) 0.77
Heart over mind: metabolic control of white adipose tissue and liver. EMBO Mol Med (2014) 0.76
Myostatin and IGF-I signaling in end-stage human heart failure: a qRT-PCR study. J Transl Med (2015) 0.76
Higher Plasma Myostatin Levels in Cor Pulmonale Secondary to Chronic Obstructive Pulmonary Disease. PLoS One (2016) 0.75
Serum Biomarkers of Myocardial Remodeling and Coronary Dysfunction in Early Stages of Hypertrophic Cardiomyopathy in the Young. Pediatr Cardiol (2017) 0.75
CREB, NF-Y and MEIS1 conserved binding sites are essential to balance Myostatin promoter/enhancer activity during early myogenesis. Mol Biol Rep (2017) 0.75
The histone deacetylase SIRT6 blocks myostatin expression and development of muscle atrophy. Sci Rep (2017) 0.75
Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature (1997) 14.82
Left ventricular assist device and drug therapy for the reversal of heart failure. N Engl J Med (2006) 8.98
Regulation of myostatin activity and muscle growth. Proc Natl Acad Sci U S A (2001) 6.38
Induction of cachexia in mice by systemically administered myostatin. Science (2002) 4.39
Myostatin signals through a transforming growth factor beta-like signaling pathway to block adipogenesis. Mol Cell Biol (2003) 2.90
Activation of latent myostatin by the BMP-1/tolloid family of metalloproteinases. Proc Natl Acad Sci U S A (2003) 2.66
Regression of cellular hypertrophy after left ventricular assist device support. Circulation (1998) 2.59
Low incidence of myocardial recovery after left ventricular assist device implantation in patients with chronic heart failure. Circulation (1998) 2.44
PI3K rescues the detrimental effects of chronic Akt activation in the heart during ischemia/reperfusion injury. J Clin Invest (2005) 2.36
Cardiac improvement during mechanical circulatory support: a prospective multicenter study of the LVAD Working Group. Circulation (2007) 2.34
Insulin-like growth factor-1 mediates stretch-induced upregulation of myostatin expression in neonatal rat cardiomyocytes. Cardiovasc Res (2005) 2.33
Organization of the human myostatin gene and expression in healthy men and HIV-infected men with muscle wasting. Proc Natl Acad Sci U S A (1998) 2.13
Myostatin directly regulates skeletal muscle fibrosis. J Biol Chem (2008) 2.11
Lower skeletal muscle mass in male transgenic mice with muscle-specific overexpression of myostatin. Am J Physiol Endocrinol Metab (2003) 1.98
Relationships between transforming growth factor-beta1, myostatin, and decorin: implications for skeletal muscle fibrosis. J Biol Chem (2007) 1.96
Myostatin, a transforming growth factor-beta superfamily member, is expressed in heart muscle and is upregulated in cardiomyocytes after infarct. J Cell Physiol (1999) 1.95
Myostatin regulates cardiomyocyte growth through modulation of Akt signaling. Circ Res (2006) 1.92
Mechanisms involved in the inhibition of myoblast proliferation and differentiation by myostatin. Exp Cell Res (2003) 1.72
Transcriptional effects of chronic Akt activation in the heart. J Biol Chem (2002) 1.65
Myostatin induces cyclin D1 degradation to cause cell cycle arrest through a phosphatidylinositol 3-kinase/AKT/GSK-3 beta pathway and is antagonized by insulin-like growth factor 1. J Biol Chem (2006) 1.55
Characterization and identification of the inhibitory domain of GDF-8 propeptide. Biochem Biophys Res Commun (2004) 1.45
Myostatin signaling through Smad2, Smad3 and Smad4 is regulated by the inhibitory Smad7 by a negative feedback mechanism. Cytokine (2004) 1.42
Regulation of GDF-8 signaling by the p38 MAPK. Cell Signal (2005) 1.32
Extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase pathway is involved in myostatin-regulated differentiation repression. Cancer Res (2006) 1.26
Myostatin expression in ventricular myocardium in a rat model of volume-overload heart failure. Eur J Clin Invest (2006) 1.22
Myostatin auto-regulates its expression by feedback loop through Smad7 dependent mechanism. J Cell Physiol (2006) 1.20
Alterations in myostatin expression are associated with changes in cardiac left ventricular mass but not ejection fraction in the mouse. J Endocrinol (2007) 1.14
Myostatin, the cardiac chalone of insulin-like growth factor-1. Cardiovasc Res (2005) 1.05
Insulin-like growth factor-1 and myostatin mRNA expression in muscle: comparison between 62-77 and 21-31 yr old men. Exp Gerontol (2002) 0.89
Effect of clenbuterol on cardiac and skeletal muscle function during left ventricular assist device support. J Heart Lung Transplant (2006) 0.88
Hypothesis: myostatin is a mediator of cardiac cachexia. Int J Cardiol (2007) 0.84
Wide ranges of serum myostatin concentrations in Duchenne muscular dystrophy patients. Clin Chim Acta (2008) 0.82
Matrix elasticity directs stem cell lineage specification. Cell (2006) 43.00
Myotubes differentiate optimally on substrates with tissue-like stiffness: pathological implications for soft or stiff microenvironments. J Cell Biol (2004) 7.38
Use of a continuous-flow device in patients awaiting heart transplantation. N Engl J Med (2007) 7.15
PTC124 targets genetic disorders caused by nonsense mutations. Nature (2007) 6.67
Outcomes of left ventricular assist device implantation as destination therapy in the post-REMATCH era: implications for patient selection. Circulation (2007) 4.67
Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med (2007) 4.20
Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation (2007) 4.16
Extended mechanical circulatory support with a continuous-flow rotary left ventricular assist device. J Am Coll Cardiol (2009) 4.03
The mechanism of myosin VI translocation and its load-induced anchoring. Cell (2004) 3.85
Mesenchymal stem cell injection after myocardial infarction improves myocardial compliance. Am J Physiol Heart Circ Physiol (2006) 3.78
A structural state of the myosin V motor without bound nucleotide. Nature (2003) 3.63
Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation. N Engl J Med (2004) 3.44
Evidence-based guidelines for cardiovascular disease prevention in women. Circulation (2004) 3.39
Three myosin V structures delineate essential features of chemo-mechanical transduction. EMBO J (2004) 3.21
Results of the post-U.S. Food and Drug Administration-approval study with a continuous flow left ventricular assist device as a bridge to heart transplantation: a prospective study using the INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support). J Am Coll Cardiol (2011) 3.06
Effects of perioperative nesiritide in patients with left ventricular dysfunction undergoing cardiac surgery:the NAPA Trial. J Am Coll Cardiol (2006) 2.88
Role of the lever arm in the processive stepping of myosin V. Proc Natl Acad Sci U S A (2002) 2.86
Muscle-specific expression of insulin-like growth factor I counters muscle decline in mdx mice. J Cell Biol (2002) 2.76
Surgical ventricular restoration in the treatment of congestive heart failure due to post-infarction ventricular dilation. J Am Coll Cardiol (2004) 2.62
Acquired von Willebrand syndrome after continuous-flow mechanical device support contributes to a high prevalence of bleeding during long-term support and at the time of transplantation. J Am Coll Cardiol (2010) 2.52
The structure of the myosin VI motor reveals the mechanism of directionality reversal. Nature (2005) 2.50
A model of myosin V processivity. J Biol Chem (2004) 2.49
Genetic and pharmacologic inhibition of mitochondrial-dependent necrosis attenuates muscular dystrophy. Nat Med (2008) 2.49
Central role of RAGE-dependent neointimal expansion in arterial restenosis. J Clin Invest (2003) 2.40
A force-dependent state controls the coordination of processive myosin V. Proc Natl Acad Sci U S A (2005) 2.39
Factors associated with primary graft failure after heart transplantation. Transplantation (2010) 2.38
Development of a novel echocardiography ramp test for speed optimization and diagnosis of device thrombosis in continuous-flow left ventricular assist devices: the Columbia ramp study. J Am Coll Cardiol (2012) 2.33
Myosin VI steps via a hand-over-hand mechanism with its lever arm undergoing fluctuations when attached to actin. J Biol Chem (2004) 2.31
Adeno-associated virus (AAV) serotype 9 provides global cardiac gene transfer superior to AAV1, AAV6, AAV7, and AAV8 in the mouse and rat. Hum Gene Ther (2008) 2.27
Glycation, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyond. Circ Res (2003) 2.25
Increased incidence of gastrointestinal bleeding following implantation of the HeartMate II LVAD. J Card Surg (2010) 2.25
Effects of continuous-flow versus pulsatile-flow left ventricular assist devices on myocardial unloading and remodeling. Circ Heart Fail (2011) 2.19
Ventricular assist device implantation corrects myocardial lipotoxicity, reverses insulin resistance, and normalizes cardiac metabolism in patients with advanced heart failure. Circulation (2012) 2.17
Resveratrol, a natural red wine polyphenol, reduces ischemia-reperfusion-induced spinal cord injury. Ann Thorac Surg (2005) 2.15
Right heart failure after left ventricular assist device implantation in patients with chronic congestive heart failure. J Heart Lung Transplant (2005) 2.05
Neovasculogenic therapy to augment perfusion and preserve viability in ischemic cardiomyopathy. Ann Thorac Surg (2006) 1.82
Full-length myosin VI dimerizes and moves processively along actin filaments upon monomer clustering. Mol Cell (2006) 1.80
Adipose tissue inflammation and adiponectin resistance in patients with advanced heart failure: correction after ventricular assist device implantation. Circ Heart Fail (2012) 1.79
A flexible domain is essential for the large step size and processivity of myosin VI. Mol Cell (2005) 1.78
Impact of center volume on outcomes of left ventricular assist device implantation as destination therapy: analysis of the Thoratec HeartMate Registry, 1998 to 2005. Circ Heart Fail (2009) 1.77
The cost of medical management in advanced heart failure during the final two years of life. J Card Fail (2008) 1.71
Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. J Am Coll Cardiol (2007) 1.69
The impact of angiotensin-converting enzyme inhibitor therapy on the extracellular collagen matrix during left ventricular assist device support in patients with end-stage heart failure. J Am Coll Cardiol (2007) 1.63
Survival after heart transplantation is not diminished among recipients with uncomplicated diabetes mellitus: an analysis of the United Network of Organ Sharing database. Circulation (2006) 1.62
Evidence-based guidelines for cardiovascular disease prevention in women. J Am Coll Cardiol (2004) 1.59
Infection in permanent circulatory support: experience from the REMATCH trial. J Heart Lung Transplant (2004) 1.56
The structural basis for the large powerstroke of myosin VI. Cell (2007) 1.56
Heart transplant and left ventricular assist device costs. J Heart Lung Transplant (2005) 1.55
Effect of donor age on long-term survival following cardiac transplantation. J Card Surg (2006) 1.54
Preoperative assessment of high-risk candidates to predict survival after heart transplantation. Circ Heart Fail (2013) 1.53
Clinical outcomes in patients with chronic congestive heart failure who undergo left ventricular assist device implantation. J Thorac Cardiovasc Surg (2005) 1.50
Improved diabetic control in advanced heart failure patients treated with left ventricular assist devices. Eur J Heart Fail (2010) 1.49
Evidence-based guidelines for cardiovascular disease prevention in women. American Heart Association scientific statement. Arterioscler Thromb Vasc Biol (2004) 1.49
Contemporary Outcomes of Venoarterial Extracorporeal Membrane Oxygenation for Refractory Cardiogenic Shock at a Large Tertiary Care Center. ASAIO J (2015) 1.48
Laser energy source in surgical atrial fibrillation ablation: preclinical experience. Ann Thorac Surg (2006) 1.47
Clenbuterol increases lean muscle mass but not endurance in patients with chronic heart failure. J Heart Lung Transplant (2008) 1.46
Which patient, which pump? J Heart Lung Transplant (2003) 1.46
Kinetic characterization of the weak binding states of myosin V. Biochemistry (2002) 1.46
Myosin IIb is unconventionally conventional. J Biol Chem (2003) 1.45
Systemic administration of L-arginine benefits mdx skeletal muscle function. Muscle Nerve (2005) 1.43
Dynamics of bone turnover markers in patients with heart failure and following haemodynamic improvement through ventricular assist device implantation. Eur J Heart Fail (2012) 1.43
Interhead distance measurements in myosin VI via SHRImP support a simplified hand-over-hand model. Biophys J (2005) 1.43
Myosin VI dimerization triggers an unfolding of a three-helix bundle in order to extend its reach. Mol Cell (2009) 1.42
Magnesium regulates ADP dissociation from myosin V. J Biol Chem (2004) 1.42
Timing of nitric oxide donor supplementation determines endothelin-1 regulation and quality of lung preservation for transplantation. Am J Respir Cell Mol Biol (2002) 1.41
Current technology: devices available for destination therapy. Cardiol Clin (2011) 1.41
Totally endoscopic atrial septal defect repair with robotic assistance. Circulation (2003) 1.40
Kinetic mechanism of blebbistatin inhibition of nonmuscle myosin IIb. Biochemistry (2004) 1.40
Viral expression of insulin-like growth factor-I enhances muscle hypertrophy in resistance-trained rats. J Appl Physiol (1985) (2004) 1.40
Outcomes of cardiac transplantation in septuagenarians. J Heart Lung Transplant (2012) 1.40
Tips on tuning each device: technical pearls. Cardiol Clin (2011) 1.39
The unique insert in myosin VI is a structural calcium-calmodulin binding site. Proc Natl Acad Sci U S A (2004) 1.38
Surgical ventricular restoration: the RESTORE Group experience. Heart Fail Rev (2004) 1.37
Coronary artery bypass grafting in patients with low ejection fraction. Circulation (2005) 1.36
Is severe right ventricular failure in left ventricular assist device recipients a risk factor for unsuccessful bridging to transplant and post-transplant mortality. Ann Thorac Surg (2004) 1.34
Cargo binding induces dimerization of myosin VI. Proc Natl Acad Sci U S A (2009) 1.34
Right ventricular dysfunction and organ failure in left ventricular assist device recipients: a continuing problem. Ann Thorac Surg (2002) 1.33
The unique insert at the end of the myosin VI motor is the sole determinant of directionality. Proc Natl Acad Sci U S A (2007) 1.30
Robotic techniques improve quality of life in patients undergoing atrial septal defect repair. Ann Thorac Surg (2004) 1.29
Patterning, prestress, and peeling dynamics of myocytes. Biophys J (2004) 1.29
Functional role of loop 2 in myosin V. Biochemistry (2004) 1.29
Clinical outcomes for continuous-flow left ventricular assist device patients stratified by pre-operative INTERMACS classification. J Heart Lung Transplant (2010) 1.28
Prevalence of de novo aortic insufficiency during long-term support with left ventricular assist devices. J Heart Lung Transplant (2010) 1.28
Rescue of dystrophic skeletal muscle by PGC-1α involves a fast to slow fiber type shift in the mdx mouse. PLoS One (2012) 1.26
Cyclin A2 induces cardiac regeneration after myocardial infarction and prevents heart failure. Circ Res (2007) 1.25
Age-related differences in lower-limb muscle cross-sectional area and torque production in boys with Duchenne muscular dystrophy. Arch Phys Med Rehabil (2010) 1.24
Myosin Va and myosin VI coordinate their steps while engaged in an in vitro tug of war during cargo transport. Proc Natl Acad Sci U S A (2011) 1.23
Bridging to transplant with the HeartMate left ventricular assist device: The Columbia Presbyterian 12-year experience. J Thorac Cardiovasc Surg (2004) 1.23
Myosin VI undergoes a 180 degrees power stroke implying an uncoupling of the front lever arm. Proc Natl Acad Sci U S A (2009) 1.23